Evidence map›Paper›PMID 38113000›Full record

ArticleCancer treatment and research2023

Recent Advances in RNA m

Michelle Verghese, Emma Wilkinson, Yu-Ying He

Abstract read
PubMed Publisher
In one paragraph

Article in Cancer treatment and research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.7field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Michelle VergheseDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.
Emma WilkinsonDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA.
Yu-Ying HeDepartment of Medicine, Section of Dermatology, University of Chicago, Chicago, IL, 60637, USA. yyhe@uchicago.edu.
University of Chicago · US

Funding

Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant (Parent T32)T32HD007009 · NICHD · UNIVERSITY OF CHICAGO · PI NANCY B SCHWARTZ · 1985 to 2026
$13.0M
NICHD NIH HHS T32 HD007009
6 · The paper itself

Abstract

An analogous field to epigenetics is referred to as epitranscriptomics, which focuses on the study of post-transcriptional chemical modifications in RNA. RNA molecules, including mRNA, tRNA, rRNA, and other non-coding RNA molecules, can be edited with numerous modifications. The most prevalent modification in eukaryotic mRNA is N6-methyladenosine (m

Indexed as

NeoplasmsRNAHumansMethylationRNA, MessengerRNA MethylationRNARNA, Messengeranti-tumor immunity.cancerchemotherapyEpitranscriptomicseraserimmunotherapym6A RNA methylationreaderwriter

Identifiers

PMID38113000
OpenAlexW4389948014

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.